Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, MedImmune Studying Role of Protein Dynamics in Neurodegenerative Diseases

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with MedImmune to study the effects of a monoclonal antibody on the dynamics of the cellular prion protein.

MedImmune, the biologics research development arm of AstraZeneca, will use KineMed's technology to track the prion protein to gain a better understanding of how an antibody directed at the cellular prion protein may affect turnover and expression of the protein at the cell surface.

KineMed's technology uses wide-scale isotopic labeling and mass spectrometry to track protein activity kinetics, which can elucidate biological pathways and disease processes.

Emeryville, Calif.-based KineMed said that cellular prion protein is found in healthy people, but in neurodegenerative conditions, such as Creutzfeldt-Jakob disease, the protein has an altered conformation and function. The prion protein has also been associated in recent research with Alzheimer's disease, the company added.

Financial and other terms of the deal were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.